Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Daiichi’s Edoxaban Steps Up As Once-Daily Competitor To Xarelto

This article was originally published in The Pink Sheet Daily

Executive Summary

Daiichi Sankyo plans to file two once-daily doses of the edoxaban for stroke prevention in atrial fibrillation, but the lowest one was associated with more ischemic strokes compared to warfarin in the ENGAGE AF-TIMI 48 study, which could limit prospects for use.

Advertisement

Related Content

Daiichi’s Edoxaban A-Fib Claim May Be Limited By Renal Function
Xarelto Indication Expansion Efforts Show That Fewer Could Be More
Deal Watch: Salix Merges With Italy’s Cosmo In Latest Tax-Inversion Play
Can Eliquis Play Catch Up? New Indication Should Help
Xarelto Falters Again In ACS Bid, As Competitors Aim To Catch Up To J&J Drug’s Label
Anticoagulant Market Spoiled By Choice? Cost May Be True Differentiator
Bayer Chief: Pharma’s Bad Rep Puts Europe Drug Business Model At Risk
Eliquis Label Looks Great, But May Leave Door Open For Pradaxa To Compete On Efficacy
Xarelto Takes Lead In Exploiting VTE Market Opportunity
FDA Pradaxa Approval Balances Efficacy And Bleeding Risk

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS075063

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel